CIK: 0001388325 · Show all filings
Period: Q1 2016 (← Previous) (Next →)
Filing Date: May 16, 2016
Total Value ($000): $912,485 (99.4% shares, 0.6% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| VTI | VANGUARD INDEX FDS | 2,837,100 | $297,385 | 32.6% | $57.39 | — | TOTAL STK MKT | 922908769 |
| — | OPHTHOTECH CORP | 4,910,487 | $207,566 | 22.7% | $32.35 | — | COM | 683745103 |
| INGN | INOGEN INC | 3,549,320 | $159,648 | 17.5% | $17.78 | +100.3% | COM | 45780L104 |
| VGK | VANGUARD INTL EQUITY INDEX F | 2,101,000 | $101,941 | 11.2% | $45.01 | — | FTSE EUROPE ETF | 922042874 |
| CRVS | CORVUS PHARMACEUTICALS INC | 3,154,046 | $45,734 | 5.0% | $14.35 | 0.0% | COM | 221015100 |
| — | COLUCID PHARMACEUTICALS INC | 3,056,563 | $18,951 | 2.1% | $8.90 | — | COM | 19716T101 |
| — | TOBIRA THERAPEUTICS INC | 2,281,405 | $18,662 | 2.0% | $17.25 | — | COM | 88883P101 |
| — | ACCELERON PHARMA INC | 673,063 | $17,762 | 1.9% | $26.39 | — | COM | 00434H108 |
| PEN | PENUMBRA, INC. | 263,191 | $12,107 | 1.3% | $43.51 | +7.4% | COM | 70975L107 |
| — | NABRIVA THERAPEUTICS AG | 874,985 | $7,840 | 0.9% | $9.50 | — | COM | 62957M104 |
| — | INVUITY INC | 936,193 | $6,759 | 0.7% | $8.80 | — | COM | 46187J205 |
| — | WRIGHT MED GROUP N V | 4,622,032 | $5,778 | 0.6% | $1.25 | — | RIGHT 03/01/2019 | N96617126 |
| — | HTG MOLECULAR DIAGNOSTICS INC | 1,280,185 | $3,674 | 0.4% | $11.15 | — | COM | 40434H104 |
| — | SPECTRANETICS CORP | 236,826 | $3,439 | 0.4% | $14.52 | — | COM | 84760C107 |
| — | TOKAI PHARMACEUTICALS INC | 470,946 | $2,642 | 0.3% | $14.41 | — | COM | 88907J107 |
| GKOS | GLAUKOS CORP | 101,106 | $1,705 | 0.2% | $26.03 | -33.4% | COM | 377322102 |
| XENE | XENON PHARMACEUTICALS INC | 127,563 | $892 | 0.1% | $14.68 | -51.0% | COM | 98420N105 |